Intestinal research

Korean Association for the Study of the Intestinal Diseases (대한장연구학회)
권호 표지
DOI QR코드

DOI QR Code

Response to hepatitis B vaccination in patients with inflammatory bowel disease: a prospective observational study in Korea

  • Chang, Ji Young (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Jung, Sung-Ae (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Moon, Chang Mo (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Kim, Seong-Eun (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Jung, Hye-Kyung (Department of Internal Medicine, Ewha Womans University School of Medicine) ;
  • Shim, Ki-Nam (Department of Internal Medicine, Ewha Womans University School of Medicine)
  • Received : 2018.01.29
  • Accepted : 2018.05.25
  • Published : 2018.10.30
⟨ Previous Next ⟩

Abstract

Background/Aims: Testing for hepatitis B virus (HBV) serologic markers and appropriate vaccination are required in the management of inflammatory bowel disease (IBD) patients. We evaluated immunogenicity for HBV in IBD patients and the response to the HBV vaccination. Methods: From May 2014 to August 2016, patients diagnosed with IBD were prospectively included and evaluated for antibody to hepatitis B surface antigen, antibody to hepatitis B core antigen, and antibody to hepatitis B surface antigen. Among the 73 patients who were confirmed with nonimmunity to HBV, 44 patients who had completed the 3-dose HBV vaccination series received a single booster vaccination, while 29 patients who had not completed the vaccinations series or were unsure of receiving the vaccination received a full vaccination series. Results: An optimal response was obtained in 70.5% of the patients in the booster group, and 89.7% of the patients in the full vaccination group. Age younger than 26 years (odds ratio [OR], 6.01; 95% confidence interval [CI], 1.15-31.32; P=0.033) and a complete previous vaccination series (OR, 0.15; 95% CI, 0.03-0.80; P=0.026) were associated with optimal vaccine response. Previous complete vaccination series (OR, 0.11; 95% CI, 0.02-0.73; P=0.022) was the only predictive factor for lower compliance. Conclusions: The response to the HBV vaccination was lower in patients older than 26 years and for those patients with a complete vaccination history. Since patients with a complete vaccination history also had poor compliance, serum HBV-titers should be checked more thoroughly, and a full vaccination series should be administered in cases when there is a negative response to the booster vaccination.

Keywords

References

  1. Altunoz ME, Senates E, Yesil A, Calhan T, Ovunc AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci 2012; 57:1039-1044. https://doi.org/10.1007/s10620-011-1980-8
  2. Huang ML, Xu XT, Shen J, Qiao YQ, Dai ZH, Ran ZH. Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study. J Crohns Colitis 2014;8:282-287. https://doi.org/10.1016/j.crohns.2013.08.017
  3. Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33:619-633. https://doi.org/10.1111/j.1365-2036.2010.04570.x
  4. Bernal I, Domenech E, Garcia-Planella E, Cabre E, Gassull MA. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. Gastroenterol Hepatol 2003;26:19-22. https://doi.org/10.1016/S0210-5705(03)70335-5
  5. Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003;30:1624-1625.
  6. Wei SC, Chang TA, Chao TH, et al. Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res 2017;15:266-284. https://doi.org/10.5217/ir.2017.15.3.266
  7. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol 2017;112:241-258. https://doi.org/10.1038/ajg.2016.537
  8. Moses J, Alkhouri N, Shannon A, et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol 2012;107:133-138. https://doi.org/10.1038/ajg.2011.295
  9. Kim H, Shin AR, Chung HH, et al. Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med 2013;28:413-419. https://doi.org/10.3904/kjim.2013.28.4.413
  10. Lee DH, Kim JH, Nam JJ, Kim HR, Shin HR. Epidemiological findings of hepatitis B infection based on 1998 National Health and Nutrition Survey in Korea. J Korean Med Sci 2002;17:457-462. https://doi.org/10.3346/jkms.2002.17.4.457
  11. Lee H, Lee H, Cho Y, Oh K, Ki M. Changes in seroprevalence of hepatitis B surface antigen and epidemiologic characteristics in the Republic of Korea, 1998-2013. Epidemiol Health 2015;37:e2015055. doi: 10.4178/epih/e2015055.
  12. Cho YK, Song BC. Prevention of viral hepatitis and vaccination. Korean J Med 2012;82:123-133. https://doi.org/10.3904/kjm.2012.82.2.123
  13. Lopez-Serrano P, Perez-Calle JL, Sanchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol 2013;19:1342-1348. https://doi.org/10.3748/wjg.v19.i9.1342
  14. Ben Musa R, Gampa A, Basu S, et al. Hepatitis B vaccination in patients with inflammatory bowel disease. World J Gastroenterol 2014;20:15358-15366. https://doi.org/10.3748/wjg.v20.i41.15358
  15. Lee YJ, Cheon JH, Kim JH, et al. Clinical efficacy of beclomethasone dipropionate in Korean patients with ulcerative colitis. Yonsei Med J 2017;58:144-149. https://doi.org/10.3349/ymj.2017.58.1.144
  16. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002;122:512-530. https://doi.org/10.1053/gast.2002.31072
  17. Park NH, Chung YH, Lee HS. Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period. Intervirology 2010;53:20-28. https://doi.org/10.1159/000252780
  18. Kim ES, Cho KB, Park KS, et al. Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients. J Clin Gastroenterol 2014;48:553-558.
  19. Yun HS, Min YW, Chang DK, et al. Factors associated with vaccination among inflammatory bowel disease patients in Korea. Korean J Gastroenterol 2013;61:203-208. https://doi.org/10.4166/kjg.2013.61.4.203
  20. Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther 2001;23:392-403. https://doi.org/10.1016/S0149-2918(01)80044-8
  21. Poorolajal J, Hooshmand E. Booster dose vaccination for preventing hepatitis B. Cochrane Database Syst Rev 2016;(6):CD008256. doi: 10.1002/14651858.CD008256.pub3.
  22. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011;53:68-75. https://doi.org/10.1093/cid/cir270
  23. Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013;10:277-285. https://doi.org/10.1038/nrgastro.2013.28
  24. Bruce MG, Bruden D, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose. J Infect Dis 2016;214:16-22. https://doi.org/10.1093/infdis/jiv748
  25. Cossio-Gil Y, Martinez-Gomez X, Campins-Marti M, et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol 2015;30:92-98. https://doi.org/10.1111/jgh.12712
  26. Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 2002;35:1368-1375. https://doi.org/10.1086/344271
  27. Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc) 2009; 132:331-335. https://doi.org/10.1016/j.medcli.2008.07.013
  28. Fattal-German M. Immunocompetence in the elderly. Ann Pharm Fr 1992;50:13-24.
  29. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008; 7:467-479. https://doi.org/10.1586/14760584.7.4.467
  30. Kim ES. Inflammatory bowel disease is no longer a risk factor of viral hepatitis infection in Asia. Intest Res 2017;15:5-6. https://doi.org/10.5217/ir.2017.15.1.5
  31. Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. World J Hepatol 2015;7:2503-2509. https://doi.org/10.4254/wjh.v7.i24.2503
  32. Agarwal N, Ollington K, Kaneshiro M, Frenck R, Melmed GY. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine 2012;30:1413-1424. https://doi.org/10.1016/j.vaccine.2011.11.109
  33. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1460-1466. https://doi.org/10.1038/ajg.2012.79
  34. Pratt PK Jr, David N, Weber HC, et al. Antibody response to hepatitis B virus vaccine is impaired in patients with inflammatory bowel disease on infliximab therapy. Inflamm Bowel Dis 2018;24:380-386. https://doi.org/10.1093/ibd/izx001
  35. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:e44-e100. doi: 10.1093/cid/cit684.
  36. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014;8:443-468. https://doi.org/10.1016/j.crohns.2013.12.013

Cited by

  1. Vaccination in the Elderly and IBD vol.17, pp.4, 2018, https://doi.org/10.1007/s11938-019-00257-y